Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP-223 Vaccine in Prostate Cancer
NCT00895466Phase 2Unknown
- Sponsor
- Biosynth
- Start
- Oct 2008
- Primary completion
- Dec 2009
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PEP-223 in prostate cancer (PCa), sponsored by Biosynth. Status: unknown.
02
Drugs
PEP-223
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00895466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00895466.